International Journal of Emerging Research in Applied Medical Sciences (IJERAMS)

Spatial Multi-Omics and Artificial Intelligence in Precision Oncology: Decoding the Tumor Ecosystem

Dr. Nikhil Arora[1], Dr. Meenal Joshi[2], Dr. Asif Ali[3], Mrs. Preeti Saha[4]

[1]Professor,Department of Cardiology, KIMS Medical College, Hyderabad, India.Nikhilarora70@gmail.com

[2]Associate Professor,Department of Pharmacology, KIMS Medical College, Hyderabad, India.Meenaljoshi31@gmail.com

[3]Assistant Professor,Department of Pathology, KIMS Medical College, Hyderabad, India.Asifali92@gmail.com

[4]Assistant Professor,Department of Medical Genetics, KIMS Medical College, Hyderabad, India.Preeti.saha08@gmail.com

ABSTRACT

Cancer remains one of the leading causes of morbidity and mortality worldwide despite remarkable advances in molecular diagnostics, targeted therapeutics, immunotherapy, and precision medicine. The biological complexity of cancer extends beyond genomic alterations and is increasingly recognized as a consequence of dynamic spatial interactions among malignant cells, immune populations, stromal components, vascular networks, and the extracellular matrix within the tumor ecosystem. Recent advances in spatial multi-omics technologies and artificial intelligence (AI) have transformed precision oncology by enabling simultaneous characterization of molecular, cellular, and spatial organization across tumor tissues. Spatial transcriptomics, spatial proteomics, spatial metabolomics, spatial epigenomics, multiplex imaging, single-cell sequencing, and computational pathology collectively generate unprecedented multidimensional datasets describing tumor architecture and biological function. Artificial intelligence—including machine learning, deep learning, graph neural networks, transformer architectures, multimodal foundation models, self-supervised learning, and generative AI—facilitates integration of these heterogeneous datasets into comprehensive computational representations that support diagnosis, prognostic prediction, biomarker discovery, therapeutic optimization, immunotherapy response prediction, and personalized medicine. Despite remarkable technological progress, important challenges remain regarding data harmonization, computational scalability, explainability, interoperability, regulatory validation, and equitable implementation. This review provides a comprehensive overview of spatial multi-omics and artificial intelligence in precision oncology, highlighting computational principles, clinical applications, emerging innovations, and future perspectives for decoding the tumor ecosystem.[1]

Keywords: Spatial multi-omics, Artificial intelligence, Precision oncology, Spatial transcriptomics, Spatial proteomics, Computational pathology, Tumor microenvironment, Machine learning, Digital pathology, Personalized medicine.

Article History

Received: 10 December 2025**; Accepted:** 18 December 2025**; Published:** 28 December 2025

Citation

Arora N.,(2025).Spatial Multi-Omics and Artificial Intelligence in Precision Oncology: Decoding the Tumor Ecosystem. *International Journal of Emerging Research in Applied Medical Sciences (IJERAMS), 1(5), 93-100.*

DOI: https://doi.org/10.65477/ijerams.v1.i5.12

1. Introduction

Cancer is a highly heterogeneous disease characterized not only by genomic instability but also by complex spatial organization involving malignant cells, immune populations, stromal fibroblasts, endothelial cells, extracellular matrix components, and diverse signaling molecules. These biological interactions collectively determine tumor progression, metastatic dissemination, therapeutic response, and clinical outcomes. Consequently, understanding cancer

requires investigation of both molecular alterations and their spatial context within intact tissue architecture.[2]

Traditional molecular profiling techniques have significantly advanced precision oncology through genomic sequencing, transcriptomics, proteomics, and metabolomics. However, these approaches frequently analyze dissociated tissue samples, resulting in loss of critical spatial information regarding cellular organization and intercellular communication. As a result, important biological relationships governing tumor evolution often remain obscured.[3]

Recent advances in spatial multi-omics technologies have fundamentally transformed cancer research by enabling simultaneous measurement of gene expression, protein abundance, metabolite distribution, epigenetic regulation, and cellular interactions while preserving tissue architecture. These technologies generate highly complex multidimensional datasets that require advanced computational methods for biological interpretation.[4]

Artificial intelligence has emerged as the enabling technology capable of integrating spatial biology, multi-omics, digital pathology, medical imaging, and longitudinal clinical information into unified computational frameworks that support personalized diagnosis, therapeutic optimization, biomarker discovery, and systems-level understanding of the tumor ecosystem.[5]

2. Evolution of Spatial Biology in Oncology

Early molecular oncology focused primarily on bulk tissue analysis, where genomic and transcriptomic measurements represented average molecular signals across heterogeneous cell populations. Although these approaches identified numerous clinically important biomarkers, they failed to capture cellular diversity and spatial organization within tumors.[6]

The introduction of single-cell sequencing significantly improved biological resolution by enabling molecular characterization of individual cells. Nevertheless, tissue dissociation disrupted anatomical relationships among neighboring cells, limiting investigation of spatial cellular interactions.

Subsequent development of spatial transcriptomics, multiplex immunofluorescence, imaging mass cytometry, spatial proteomics, spatial metabolomics, and advanced microscopy technologies enabled comprehensive molecular profiling while preserving tissue architecture. These innovations created unprecedented opportunities to investigate tumor ecosystems with cellular and spatial precision.[7]

Simultaneously, artificial intelligence evolved from conventional machine learning toward multimodal foundation models, graph neural networks, transformer architectures, and self-supervised learning capable of analyzing the extraordinary complexity of spatial biological datasets. Together, these advances have established spatial multi-omics as one of the most rapidly evolving fields within precision oncology.[8]

3. Principles of Spatial Multi-Omics

Spatial multi-omics integrates multiple molecular modalities while preserving the anatomical organization of biological tissues. Rather than analyzing isolated molecular datasets independently, spatial technologies simultaneously characterize gene expression, protein abundance, metabolite distribution, epigenetic regulation, immune-cell composition, and cellular interactions within their native tissue environment.[9]

Spatial transcriptomics measures messenger RNA expression while maintaining precise spatial localization across tissue sections. Spatial proteomics characterizes protein abundance and signaling pathways, whereas spatial metabolomics identifies metabolic gradients associated with tumor progression. Spatial epigenomics evaluates chromatin accessibility and DNA methylation patterns, providing additional insight into gene regulation within specific anatomical regions.

Integration of these complementary molecular layers enables comprehensive characterization of tumor biology at unprecedented spatial resolution while supporting investigation of cellular communication, tissue organization, and microenvironmental dynamics.[10]

4. Artificial Intelligence for Spatial Multi-Omics Integration

Spatial multi-omics generates exceptionally high-dimensional datasets containing millions of molecular measurements distributed across thousands of spatial locations. Artificial intelligence has become indispensable for integrating these heterogeneous datasets into biologically meaningful computational representations.[11]

Machine learning algorithms identify complex nonlinear relationships among spatial molecular features, whereas deep learning automatically extracts hierarchical biological representations without requiring manual feature engineering. Transformer architectures efficiently integrate multiple molecular modalities while preserving long-range spatial dependencies.

Graph neural networks are particularly valuable because they naturally represent cellular interaction networks involving neighboring cells, signaling pathways, immune communication, vascular structures, and extracellular matrix organization. These graph-based computational models capture spatial biological relationships that conventional analytical methods cannot adequately represent.

Multimodal foundation models further strengthen computational integration by simultaneously learning from digital pathology, radiological imaging, spatial transcriptomics, proteomics, metabolomics, and longitudinal clinical information within unified patient-specific computational frameworks.[12]

5. Spatial Transcriptomics

Spatial transcriptomics has become one of the most influential technologies in precision oncology because it enables comprehensive mapping of gene expression while preserving tissue architecture. Unlike conventional transcriptomic analyses that lose spatial information through tissue dissociation, spatial transcriptomics identifies where genes are expressed within intact tumors.[13]

Artificial intelligence analyzes these high-dimensional gene-expression maps to identify molecular niches, cellular neighborhoods, developmental trajectories, immune interactions, and biological gradients associated with tumor progression. Deep learning further integrates transcriptomic information with pathology, imaging, and clinical variables to improve diagnosis, prognostic prediction, and therapeutic selection.

Spatial transcriptomics has significantly enhanced understanding of intratumoral heterogeneity by revealing distinct molecular regions that contribute to therapeutic resistance, metastasis, and disease recurrence.[14]

6. Spatial Proteomics and Functional Biology

Proteins represent the functional molecules responsible for virtually all biological activities within tumors. Spatial proteomics extends genomic and transcriptomic analyses by directly measuring protein abundance, localization, signaling pathways, and post-translational modifications while preserving tissue architecture.[15]

Artificial intelligence enables comprehensive analysis of large-scale spatial proteomic datasets generated through imaging mass cytometry, multiplex immunohistochemistry, multiplex immunofluorescence, and related technologies. Machine learning identifies protein signatures associated with diagnosis, therapeutic response, immune activation, angiogenesis, and metastatic potential.

Integration of spatial proteomics with transcriptomics, genomics, and digital pathology provides increasingly comprehensive representations of tumor biology while supporting discovery of clinically actionable biomarkers and therapeutic targets.[16]

7. Spatial Metabolomics and Tumor Metabolism

Cancer metabolism varies considerably across different anatomical regions within tumors because of oxygen availability, vascularization, nutrient gradients, immune infiltration, and cellular heterogeneity. Spatial metabolomics enables visualization of metabolic pathways while preserving tissue organization, providing direct insight into functional tumor biology.[17]

Artificial intelligence analyzes spatial metabolomic profiles together with transcriptomics, proteomics, pathology, and imaging to identify metabolic signatures associated with tumor aggressiveness, treatment resistance, immune suppression, and metastatic dissemination.

These computational approaches improve understanding of metabolic heterogeneity while facilitating development of novel metabolic biomarkers and personalized therapeutic strategies targeting tumor-specific metabolic vulnerabilities.[18]

8. Spatial Characterization of the Tumor Microenvironment

The tumor microenvironment comprises malignant cells together with immune populations, stromal fibroblasts, endothelial cells, extracellular matrix components, cytokines, and diverse signaling molecules that collectively regulate cancer progression. Spatial multi-omics provides unprecedented opportunities to investigate these cellular interactions within intact tissue architecture.[19]

Artificial intelligence quantifies tumor-infiltrating lymphocytes, macrophages, fibroblasts, vascular networks, immune checkpoint expression, cytokine gradients, stromal organization, and spatial cellular neighborhoods to characterize the biological complexity of individual tumors.

These computational analyses improve prediction of immunotherapy responsiveness, therapeutic resistance, metastatic potential, and long-term clinical outcomes while supporting increasingly personalized precision oncology through detailed understanding of the tumor ecosystem.[20]

9. Artificial Intelligence for Spatial Biomarker Discovery

One of the greatest strengths of spatial multi-omics lies in its ability to identify novel biomarkers that incorporate both molecular characteristics and spatial organization. Artificial intelligence integrates spatial transcriptomics, proteomics, metabolomics, epigenomics, digital pathology, radiological imaging, and clinical outcomes to discover biomarkers that more accurately predict diagnosis, prognosis, treatment response, and disease recurrence than conventional molecular signatures alone.[21]

Machine learning algorithms identify spatial cellular neighborhoods, signaling gradients, immune-cell distributions, vascular organization, and metabolic patterns associated with aggressive tumor behavior or therapeutic sensitivity. These computationally derived biomarkers improve molecular classification while supporting increasingly personalized treatment selection.

As larger spatial datasets become available, artificial intelligence is expected to facilitate discovery of robust multimodal biomarkers applicable across diverse cancer types and healthcare settings.

10. Precision Therapeutics and Personalized Oncology

Spatial multi-omics provides comprehensive biological insight that supports highly individualized cancer treatment. Artificial intelligence combines spatial molecular information with radiological imaging, pathology, laboratory biomarkers, genomic sequencing, treatment history, and longitudinal clinical records to predict therapeutic response across multiple treatment modalities.[22]

Computational models estimate recurrence probability, progression-free survival, overall survival, treatment-related toxicity, and mechanisms of therapeutic resistance while evaluating chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, surgery, and combination treatment strategies.

Because spatial biological organization continuously influences tumor evolution, integration of spatial multi-omics enables more accurate therapeutic predictions than conventional molecular profiling alone, thereby strengthening precision medicine.

11. Spatial Multi-Omics in Immunotherapy

The tumor immune microenvironment plays a decisive role in determining responsiveness to immunotherapy. Spatial multi-omics enables simultaneous evaluation of immune-cell localization, cytokine signaling, immune

checkpoint expression, stromal remodeling, antigen presentation, and cellular communication while preserving tissue architecture.[23]

Artificial intelligence analyzes spatial distributions of tumor-infiltrating lymphocytes, macrophages, dendritic cells, fibroblasts, endothelial cells, and regulatory immune populations to predict responsiveness to immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, bispecific antibodies, and adoptive cellular therapies.

These computational approaches identify immune niches associated with treatment resistance and facilitate individualized immunotherapeutic strategies based upon each patient's unique spatial immune landscape.

12. Digital Pathology, Radiomics, and Multimodal Integration

Spatial multi-omics becomes even more powerful when integrated with computational pathology and advanced medical imaging. Digital pathology provides microscopic visualization of tissue architecture, whereas radiomics extracts quantitative imaging biomarkers describing tumor morphology, vascularity, heterogeneity, texture, and spatial organization.[24]

Multimodal artificial intelligence integrates radiological imaging, computational pathology, spatial transcriptomics, proteomics, metabolomics, laboratory biomarkers, and clinical documentation into unified computational representations of tumor biology.

These integrated computational ecosystems improve diagnosis, molecular subtype classification, therapeutic prediction, disease monitoring, and prognostic assessment while supporting increasingly comprehensive precision oncology.

13. Digital Twins and Spatial Computational Oncology

The convergence of spatial multi-omics with digital twin technology is creating continuously evolving virtual representations of individual tumors that integrate molecular biology, spatial tissue organization, imaging, pathology, laboratory investigations, and longitudinal clinical information into dynamic computational models.[25]

Artificial intelligence continuously updates these digital twins as new spatial biological information becomes available, allowing simulation of tumor evolution, immune interactions, therapeutic response, recurrence, and treatment-related toxicity.

By combining spatial biology with virtual patient modeling, digital twins provide unprecedented opportunities for adaptive therapeutic planning, personalized clinical decision support, and continuous disease monitoring throughout the cancer care continuum.

14. Explainable Artificial Intelligence and Clinical Translation

Successful implementation of spatial multi-omics within precision oncology depends upon transparency, interpretability, and clinician confidence. Explainable artificial intelligence (XAI) enables researchers and clinicians to understand computational predictions through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution methods, and counterfactual reasoning that identify biologically meaningful spatial features contributing to model predictions.[26]

Nevertheless, important implementation challenges remain. Spatial datasets are exceptionally large, heterogeneous, and computationally demanding. Differences in tissue preparation, imaging platforms, molecular technologies, annotation standards, and institutional workflows create substantial interoperability challenges.

Additional concerns include algorithmic bias, patient privacy, regulatory approval, cybersecurity, equitable access, and the need for prospective multicenter clinical validation before routine implementation.

15. Future Perspectives

Rapid advances in computational biology continue to expand the capabilities of spatial multi-omics and artificial intelligence. Foundation models trained on multimodal spatial

datasets are expected to improve biomarker discovery, molecular characterization, therapeutic prediction, and systems biology while requiring less task-specific retraining.[27]

Emerging technologies including single-cell multi-omics, spatial epigenomics, liquid biopsy, quantum computing, federated learning, agentic artificial intelligence, generative AI, cloud-native computational infrastructure, and wearable biosensors will further strengthen precision oncology ecosystems.

Future computational platforms may continuously integrate spatial biology, radiology, pathology, genomics, digital twins, and longitudinal clinical information into intelligent systems capable of adaptive clinical reasoning, personalized therapeutics, and real-time disease monitoring.

16. Discussion

Spatial multi-omics has fundamentally transformed precision oncology by enabling comprehensive characterization of tumor biology within its native tissue environment. Integration of spatial transcriptomics, proteomics, metabolomics, digital pathology, radiomics, and artificial intelligence provides unprecedented insight into tumor heterogeneity, immune interactions, stromal organization, and cellular communication that cannot be obtained through conventional molecular analyses alone.[28]

Applications spanning biomarker discovery, precision diagnosis, immunotherapy prediction, computational pathology, digital twins, personalized therapeutics, and systems biology demonstrate the extraordinary potential of these technologies for improving individualized cancer care.

Nevertheless, successful clinical translation requires standardized computational pipelines, explainable artificial intelligence, robust interoperability, secure computational infrastructure, prospective validation studies, and close collaboration among clinicians, computational scientists, molecular biologists, pathologists, engineers, and regulatory agencies.

17. Conclusion

Spatial multi-omics and artificial intelligence are redefining precision oncology by integrating molecular biology with spatial tissue architecture into comprehensive computational frameworks capable of decoding the tumor ecosystem. Through simultaneous analysis of transcriptomics, proteomics, metabolomics, digital pathology, radiological imaging, laboratory biomarkers, and longitudinal clinical information, these technologies support increasingly personalized diagnosis, prognostic prediction, therapeutic optimization, and disease monitoring.[29]

As multimodal foundation models, graph neural networks, digital twins, agentic artificial intelligence, federated learning, spatial biology, and cloud-based computational infrastructure continue to evolve, their clinical applications are expected to expand substantially. Although important scientific, technical, ethical, and regulatory challenges remain, continued interdisciplinary collaboration will accelerate responsible implementation of spatial multi-omics in routine oncology practice.

By revealing the spatial organization of cancer at unprecedented biological resolution, these emerging technologies have the potential to transform precision medicine from molecular characterization alone toward comprehensive understanding of the entire tumor ecosystem, ultimately improving clinical outcomes and advancing the future of personalized cancer care.[30]

18. References

1.Synthia, F. et al. (2020) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.

2.Dr.Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415,

https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12

3.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18

4.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7

5.Dr.Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325,DOI: https://doi.org/10.46121/pspc.52.4.14

6.Dr.Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31

7.Dr.Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21

8.Dr.Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16

9.Dr.Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33

10.Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.

11.Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.

12.Dr.Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.

13.Dr.Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8

14.Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.

15.Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.

16.Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.

17.Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.

18.Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.

19.Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.

20.Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.

21.Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.

22.Wei, L. et al. (2023) 'Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration', British Journal of Radiology, 96(1150), Article 20230211.

23.Boehm, K.M. et al. (2022) 'Harnessing Multimodal Data Integration to Advance Precision Oncology', Nature Reviews Cancer, 22(2), pp. 114–126.

24.Dr.Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4

25.Dr.Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7

26.Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.

27.Dr.Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5

28.Dr.Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5

29.Dr.Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38

30.Dr.Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14